Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Abstract

A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al.

• Authors: Vincent F Simmon
• Journal: Trials (Trials) Vol. 10 Pg. 110; author reply 111 (Dec 03 2009) ISSN: 1745-6215 [Electronic] England
• PMID: 19958522 (Publication Type: Comment, Letter)

Chemical References

• Bradykinin B2 Receptor Antagonists
• LF 16-0687
• Placebos
• Quinolines

Topics

• Bradykinin B2 Receptor Antagonists
• Brain Injuries (drug therapy)
• Humans
• Placebos
• Quinolines (therapeutic use)
• Randomized Controlled Trials as Topic